Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenosquamous carcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-LUNG02
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 04 Jun 2024 Results assessing updated efficacy and safety results from the final analysis of DESTINY-Lung02 were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 21 May 2024 According to Daiichi Sankyo media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology Scientific Program
    • 25 Mar 2024 Planned End Date changed from 1 Sep 2023 to 31 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top